Presentation of immunogenicity related information in regulatory dossiers
In this supplement Paul Chamberlain explains how an integrated summary report can be created to consolidate the information required for assessment of immunogenicity-related risks of different types of biopharmaceuticals.
Fill out the form on the right to download this article.
Your drug development needs are unique
Contact us to learn how our experts can support you to meet all regulatory, quality and safety requirements and ensure the best path to approval.
Let's Bring Medicines to the World